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Synthetic cathinones are new psychoactive substances that represent a health risk worldwide. For most
of the 130 reported compounds, information about toxicology and/or metabolism is not available, which
hampers their detection (and subsequent medical treatment) in intoxication cases. The principles of
forensic analytical chemistry and the use of powerful analytical techniques are indispensable for stab-
lishing the most appropriate biomarkers for these substances. Human metabolic fate of synthetic
cathinones can be assessed by the analysis of urine and blood obtained from authentic consumers;
however, this type of samples is limited and difficult to access. In this work, the metabolic behaviour of
three synthetic cathinones (4-CEC, 4-CPrC and 5-PPDi) and one amphetamine (3-FEA) has been evalu-
ated by incubation with pooled human hepatocytes and metabolite identification has been performed by
high-resolution mass spectrometry. This in vitro approach has previously shown its feasibility for
obtaining excretory human metabolites. 4-CEC and 3-FEA were not metabolised, and for 4-CPrC only two
minor metabolites were obtained. On the contrary, for the recently reported 5-PPDi, twelve phase I
metabolites were elucidated. Up to our knowledge, this is the first metabolic study of an indanyl-
cathinone. Data reported in this paper will allow the detection of these synthetic stimulants in intoxi-
cation cases, and will facilitate future research on the metabolic behaviour of other indanyl-based
cathinones.
© 2019 Xi'an Jiaotong University. Production and hosting by Elsevier B.V. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Synthetic cathinones are one of the largest groups of new psy-
choactive substances (NPS), with around 130 compounds being
monitored by the EuropeanMonitoring of Drug and Drug Addiction
(EMCDDA) [1]. They constitute the second group most frequently
seized in Europe (around 33% of seizures containing NPS), being a-
PVP, 4-CMC, 3-CMC, 4-CEC and 3-MMC the most commonly found
compounds [1]. In 2017, 12 novel synthetic cathinones were
detected for the first time in Europe [1], which suggests the
continuous expansion of this non-legal market.
The fast emerging of these NPS is evidenced by a number ofUniversity.
n and hosting by Elsevier B.V. Thisresearch papers reporting novel cathinones [2e8]. This fact re-
marks the need of analytical strategies for monitoring the large
number of cathinones already reported but also the constant
apparition of new ones. Regarding consumption products, high-
resolution mass spectrometry (HRMS) is one of the most power-
ful techniques for cathinones identification, as it allows the non-
target and suspect analysis based on full-spectrum mass-accurate
data provided by this technique [4,5,9,10]. However, facing the
problem that synthetic cathinones consumption cannot be limited
to only the analysis of legal highs and seizures, forensic and clinical
analytical chemistry plays an important role in the monitoring of
NPS in biological matrices. Several UHPLC-MS/MS and UHPLC-
HRMS target methodologies have been applied for the determina-
tion of synthetic cathinones in hair [11], oral fluid [12], urine [13],
and even wastewater [14]. Nevertheless, most current methodol-
ogies are focused on the determination of synthetic cathinones as
unaltered compounds. The lack of information about the metabolicis an open access article under the CC BY-NC-ND license (http://creativecommons.
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cation cases, as they are commonly partially or totally metabolised.
So, it is of utmost importance to study the pharmacology and
metabolic behaviour of these compounds, trying to establish the
most suitable biomarkers for their monitoring, especially for the
most recently detected cathinones in the continuously moving
“market” of NPS.
Ideally, human samples, mainly blood and urine, should be used
but these samples are difficult to access and limited to authentic
intoxication cases [15e21]. As an alternative, the in vitro approach,
using pooled human liver microsomes (pHLM), pooled human S9
fraction (pS9) or pooled human hepatocytes (pHH) can be applied
to the study of human excretory metabolites [22,23]. Among them,
pHH seem to provide the best realistic pattern of metabolites [24],
with most of them being detected in authentic urine samples from
intoxication cases [20,25,26].
In this work, incubation with pHH was applied for investigating
the metabolic behaviour of three synthetic cathinones and one
amphetamine: the recently reported 3,4-trimethylene-a-pyrroli-
dinobutiophenone (5-PPDi) [27], 4-chloro-a-pyrrolidinopropio-
phenone (4-CPrC or 4-chloro-PPP [3]), 4-chloroethcathinone (4-
CEC [28]), and 3-fluoroethamphetamine (3-FEA [29]) (Fig. 1).
Metabolite identification was performed by UHPLC-HRMS. The
results showed that 3-FEA and 4-CEC were not metabolised by
pHH, while only 2 metabolites were detected for 4-CPrC. On the
contrary, up to 12 phase I metabolites were elucidated for 5-PPDi.
To our knowledge, this is the first study reporting the metabolic
profile of an indanyl-cathinone. Data reported in this paper will
allow to focus future analysis of urine from intoxication cases and
hospital emergences associated with the consumption of cath-
inones and amphetamines.2. Materials and methods
2.1. Reagents and chemicals
Research chemical samples containing 5-PPDi, 4-CPrC, 4-CEC
and 3-FEA were kindly provided by Energy Control (Asociacion
Bienestar y Desarrollo, Barcelona, Spain), and compound purity was
tested by nuclear magnetic resonance. MDMA-d5 (used as internal
standard) was purchased from Cerilliant (Round Rock, TX, USA).
Diclofenac was purchased from Sigma-Aldrich (St. Louis, MO, USA).
Reagents used in the incubation (0.4% trypan blue solution, fetal
bovine serum, Leibovitz’s L-15 medium, Gibco cryopreserved he-
patocyte recovery medium), solvents (methanol, acetonitrile, ul-
trapure water), formic acid (LC‒MS grade) as well as mass
calibration solutions (Pierce® LTQ Velos ESI positive Ion calibration
solution, Pierce™ ESI negative ion calibration solution) were ob-
tained from Fisher Scientific (Leicestershire, UK). The pHH wereFig. 1. Structure of the three cathinones (5-PPDi, 4-CPrC and 4-CEC) and the
amphetamine (3-FEA).purchased from Lonza (Basel, Switzerland), and stored in liquid
nitrogen until use.
2.2. pHH incubation
Cryopreserved pHH were used in this work. Information about
the incubation procedure applied can be found in literature [23].
The four tested compounds and diclofenac (used as positive
control to test the feasibility of incubations) were added at a final
concentration of 10 mM. Controls without the addition of hepato-
cytes were run simultaneously to identify hydrolysis products and
artefacts. Aliquots of 20 mL were collected after 0, 60, and 180min of
incubation andmixed with 80 mL of an ice-cold acetonitrile solution
containing 100 ng/mL of internal standard. The extracts were
frozen until analysis.
2.3. Instrumentation
Extracts were analysed using a Dionex Ultimate 3000 UHPLC
system from Thermo Scientific (Germering, Germany) coupled to a
Q Exactive high resolution mass spectrometer from Thermo Sci-
entific (Bremen, Germany) equipped with a hybrid quadrupole-
Orbitrap mass analyzer.
Chromatographic separation was performed using an Acquity
HSS C18 (2.1 mm  150 mm,1.8 mm) analytical column fromWaters
(Wexford, Ireland). The mobile phase consisted of water with 5 mM
ammonium formiate and 0.1% (v/v) formic acid (solvent A), and
acetonitrile with 0.1% (v/v) formic acid (solvent B). Flow ratewas set
to 0.25mL/min, maintaining the column at 40 C. A 14min gradient
was used, changing the composition as follows: 5% B (0e0.5 min),
70% B (0.5e9.95min), and 99% B (9.9e10.0 min), where it remained
isocratic for 2 min and followed by re-equilibration for 2 min.
Samples were kept at 5 C, and the injection volume was 3 mL.
HRMS was equipped with a heated electrospray ionization
source (HESI-II) working in positive (ESIþ) and negative (ESI‒)
ionization modes. The capillary temperature was 350 C, and the
spray voltage was 4.0 kV in ESIþ and 4.0 kV in ESI‒. Data were
acquired using data-dependent acquisition (dd-MS2, DDA) and
parallel reaction monitoring (PRM, MS/MS). Full-scan data (FTMS)
were collected in a scan-range ofm/z 200e900 using a resolution of
70,000 FWHM. DDA MS/MS was acquired at a resolution of 35,000
FWHM, while PRM were acquired at 17,500 FWHM. Nitrogen was
used as the collision gas at normalized collision energy (NCE) of 10,
30 or 50 eV. Data processing was performed using Compound
Discoverer 2.0 software (Thermo Scientific) for a preliminary
compound identification, and FreeStyle 1.3 (Thermo Scientific) for
working with raw data. Further details about HRMS instrumenta-
tion can be found in literature [23].
3. Results and discussion
3.1. Analytical strategy for metabolite identification
Compound Discoverer 2.0 software was selected for UHPLC-
HRMS DDA data processing. Based on the structure of the
selected compounds, a list of expected biotransformations (and
their combinations) (Table S1) were selected for obtaining potential
metabolites. Extracted ion chromatograms (EIC) with a mass win-
dow of ±5 ppm were automatically performed for searching the
(de)protonated molecule of the expected metabolites in the full-
scan function of the DDA acquisition. If a chromatographic peak
was detected, it was compared with the blank and stability in-
cubations, in order to discard false positives. Additionally, a binary
comparison between blank incubations and compound incubations
was performed for unexpected metabolites detection. Once the
D. Fabregat-Safont et al. / Journal of Pharmaceutical Analysis 10 (2020) 147e156 149potential metabolites were selected, MS/MS spectra acquired dur-
ing DDA acquisition were manually processed using FreeStyle 1.3
software. When a potential metabolite presented a fragmentation
which fits with its expected biotransformation, it was re-analysed
using PRM acquisition at three different collision energies (10, 30
and 50 eV). The PRM fragmentation of the metabolite was
compared with the fragmentation pathway of parent compound.
Based on this information, the position, where the biotransforma-
tion occurred, was determined, and the structure of the metabolite
was suggested. In order to enhance the confidence in the structure
elucidation, fragmentation pathways were proposed for all me-
tabolites. The present work includes an (extremely) detailed
explanation of the identification of metabolites based on the
observed PRM fragmentation.
For the studied compounds, no additional metabolites in ESI‒
were observed.
3.2. Fragmentation pathway of 5-PPDi
The first step in the metabolite elucidation strategy applied was
the in-depth study of the mass fragmentation behaviour of the
parent compound (C17H24NOþ, m/z 258.1851, 0.9 ppm). Table 1
shows the information obtained on the 5-PPDi fragmentation,
including accurate mass, elemental composition and mass error.
Fig. 2B shows the MS/MS fragmentation spectrum at 50 eV (MS/MS
spectra at 10 and 30 eV can be found in Fig. S1).
Fig. 2A shows the proposed fragmentation pathway for 5-PPDi.
The fragmentation starts with the disconnection of the different
bonds of the a-carbon atom. On the one hand, the minor product
ion at m/z 229 corresponded to the homolytic dealkylation from
parent compound. On the other hand, a product ion atm/z 187 was
obtained after the loss of the pyrrolidine moiety. A subsequent CO
loss and structure rearrangement led to the ion m/z 159. Product
ions atm/z 117 and 131were obtained after an alkylic disconnection
from m/z 159, depending on the CeC bond disconnected. Product
ion m/z 145 corresponded to the disconnection of the bond be-
tween the carbonyl and the a-carbon atom, releasing the alkylic
chain and pyrrolidine moiety. Alternatively, product ion m/z 117
could be also obtained after a CO loss from product ionm/z 145. The
pyrrolidine moiety ion (product ion m/z 72) was also observed as a
product ion, similarly to the ion corresponding to the alkylic chain
and pyrrolidine moiety (product ion m/z 112). In this case, m/z 112
produced also the product ions atm/z 84 and 70, corresponding the
first one to the alkylic chain CeC bond disconnection and the sec-
ond one to the N-dealkylation.
3.3. 5-PPDi metabolites elucidation
12 phase I metabolites were found after incubation. Six of these
metabolites corresponded to hydroxylated compounds (M1-M6).
Similarly, two metabolites corresponding to hydroxylation plus
oxidation (M10 and M11), and two with ring opening and carbox-
ylation (M8 and M9) were detected. The correct position of the
biotransformation was determined after an accurate study of the
observed PRM fragmentation. Additionally, metabolites corre-
sponding to oxidation (M7) and double oxidation (M12) were also
found. Table 1 shows the accurate mass, elemental composition,
observed fragmentation, and mass error for the 12 identified
metabolites.
3.3.1. Metabolite M1
The molecular formula obtained for metabolite M1 (m/z
274.1799, C17H24NO2þ, 0.9 ppm) corresponded to a hydroxylation.
Product ion at m/z 161 suggested the hydroxyl group to be in the
aromatic moiety, based on the 16 Da shift respect thecorresponding product ion of 5-PPDi (m/z 145). Moreover, the
product ion at m/z 185 (C13H13Oþ) revealed that this product ion
corresponded to the 187 observed for the parent compound
(C13H15Oþ) but with a -2 Da shift, this is, with an additional insa-
turation. This would point out where the water loss had occurred.
Based on both premises, the hydroxyl group was located on the
trimethylene moiety (if it was in the aromatic ring, a water loss
would not be possible). The other observed product ions could be
satisfactorily justified based on the proposed structure. Fig. S2
shows the PRM spectra for M1, and Fig. S3 the proposed frag-
mentation pathway.
3.3.2. Metabolite M2
M2 was detected at m/z 274.1800 (C17H24NO2þ, 0.7 ppm). In
this case, the observed fragmentation (Table 1, Fig. S4) indicated the
hydroxyl group to be on the aromatic ring. Thus, the product ion at
m/z 158 (C11H10Oþ) could only be justified if the hydroxyl group
was in the aromatic ring (Fig. S5). This allowed the loss of a water
molecule from the carbonyl group (m/z 256), as the subsequent
insaturation could be stabilised by the aromatic ring. After that,
product ions at m/z 227 and 143 were produced, depending on
which bond was disconnected. With this assumption, the frag-
mentation pathway was proposed, fitting the observed fragmen-
tation with the proposed structure. In order to facilitate the
visualisation of the electronic rearrangement during fragmentation
pathway, the hydroxylation has been placed in a certain atom of the
aromatic ring.
3.3.3. Metabolites M3 and M4
M3 and M4 were observed at m/z 274.1798 and 274.1799 cor-
responding to C17H24NO2þ (1.1 and 0.9 ppm, respectively). Both
metabolites presented exactly the same PRM fragmentation
(available in Fig. S6 and S8). The productions at m/z 72 (C4H10Nþ)
and 70 (C4H8Nþ) indicated that the hydroxylation did not occur in
the pyrrolidine moiety. The product ionm/z 203 was the equivalent
to the 187 of 5-PPDi, but with a chemical shift of 16 Da. This would
locate the hydroxyl group to be on the aromatic moiety or the
alkylic chain. Product ion at m/z 131 excluded the possibility of
hydroxylation in the aromatic moiety whereas product ion at m/z
112 suggested that the alkylic chain remained unaltered. Never-
theless, if the hydroxylation point was located in the alkylic chain, it
was possible to obtain the product ion m/z 112 after an intra-
molecular nucleophilic substitution (type SN2). Thus, M3 would
correspond to the hydroxylation in the methyl group of the alkylic
chain and M4 in the methylene (or vice-versa). Finally, fragmen-
tation pathways of M3 (Fig. S7) and M4 (Fig. S9) were proposed
(similarly toM2, the hydroxylation is placed in a certain atom of the
alkylic chain in order to facilitate the visualisation of the electronic
rearrangement).
3.3.4. Metabolite M5
The molecular formula obtained for metabolite 5 corresponded,
again, to a hydroxylated metabolite (m/z 274.1799, C17H24NO2þ,
0.7 ppm). In this case, the PRM at 50 eV showed a complex
fragmentation spectra, with up to 12 product ions (Table 1). As
some of the product ions were also observed for 5-PPDi (m/z 159,
145, 131, 117), the hydroxylation in the aromatic ring was discarded.
Product ions m/z 245, 128 and 100 (all of them with a 16 Da shift
from 5-PPDi product ions) were crucial for locating the correct
position of the biotransformation. Thus, the hydroxylation was
situated in the a-carbon atom. The product ion at m/z 85 (C4H5O2þ),
corresponding to the alkylic chain and the carbonyl, enhanced the
confidence on the metabolite structure. The proposed structure for
M5 could justify all the observed PRM product ions (Fig. S10), and
its fragmentation pathway (Fig. S11) was proposed.
Table 1
Mass spectrometric detection of 5-PPDi and its metabolites. Data obtained from PRM spectra.
Compound Retention time (min) [MþH]þ (m/z) Elemental composition Mass error (ppm)a Product ion (m/z) Elemental composition Mass error (ppm)a
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M12 8.20 286.1434 C17H20NO3þ 1.4 159.0803 C11H11Oþ 0.6
126.0916 C7H12NOþ 2
a Mass error (ppm) is shown with only one significant figure.
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M6 was the last hydroxylated metabolite, observed at m/z
274.1801 (C17H24NO2þ, 0.3 ppm). The position of the hydroxyl-
ation was easily assigned to be in the pyrrolidine moiety based on
the product ions observed at m/z 88 and 86 (16 Da shifted from 5-
PPDi product ions at m/z 72 and 70, respectively). In this case, only
5 product ions were observed in PRM spectra (Fig. S12), being all of
them justified based on the proposed structure and fragmentation
pathway (Fig. S13).3.3.6. Metabolite M7
M7 corresponded to an oxidized metabolite, based on its
elemental composition (m/z 272.1644, C17H22NO2þ,0.3 ppm). This
metabolite presented a similar fragmentation to M1 (hydroxylation
in the trimethylene moiety of the indanyl), but with some product
ions shifted 16 Da (m/z 201 vs 185, 173 vs 157, and 145 vs 129). It is
not surprising that some hydroxylated metabolites become
oxidized, generating a ketone group which cannot be lost as water
molecule. With this premise, the ketone group was placed on the
indanyl ring, trying to justify all the observed PRM product ions
(Table 1, Fig. S14). Product ions at m/z 173 and 159 guarantee the
biotransformation location. The proposed fragmentation pathway
(Fig. S15) fitted perfectly with this biotransformation.3.3.7. Metabolite M8
M8 exhibited a molecular formula containing 2 oxygen atoms
more than parent compound (m/z 290.1750, C17H24NO3þ,0.2 ppm), which could fit with a double hydroxylation or with a
ring opening followed by a carboxylation. Product ionm/z 177, with
a 32 Da chemical shift respect the m/z 145 of 5-PPDi, revealed a
possible double hydroxylation on the indanyl moiety. Nevertheless,
it is hardly difficult to observe double hydroxylations in cathinones
after pHH incubation [24], and the most common biotransforma-
tion described in literature for these compounds is the pyrrolidine
ring opening followed by carboxylation [19,21,24]. So, it was pro-
posed a ring-opening and carboxylation in the indanyl moiety,
which perfectly fit with the observed PRM fragmentation (Table 1,
Fig. S16). The fragmentation pathway (Fig. 3A) was finally proposed,
taking into account the fragmentation pathway described in liter-
ature for MDPV [19]. Product ion atm/z 119 was determined, as it is
more feasible to produce this fragmentation with a ring opening
carboxylation, instead of double hydroxylation. Nevertheless, it is
not possible to completely rule out the double hydroxylation based
only on the presence of product ion m/z 119. For an unequivocal
identification, analytical standard of both compounds should be
needed for retention time and fragmentation comparison, or the
use of additional analytical techniques such as nuclear magnetic
resonance.3.3.8. Metabolite M9
M9 presented the same elemental composition than M8 (m/z
290.1749, C17H24NO3þ, 0.3 ppm). In this case, the rich PRM frag-
mentation spectra obtained (Fig. S17), and more concretely the
product ions at m/z 272 (C17H22NO2þ), 187 (C13H15Oþ) and 87
Fig. 2. Mass spectrometric behaviour of 5-PPDi. (A) Proposed fragmentation pathway. (B) PRM spectrum at 50 eV.
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tion of the alkylic chain obtained [19,21,24]. The 16 product ions
observed in PRM spectra were satisfactorily justified using the
fragmentation pathway reported for MDPV-COOH metabolite [19],
and the fragmentation pathway of M9 was established (Fig. S18).3.3.9. Metabolites M10 and M11
M10 and M11 presented the same proposed elemental compo-
sition (m/z 288.1593 and 288.1594, C17H22NO3þ, 一0.30 and
0.01 ppm, respectively), which could match with a hydroxylation
plus oxidation (carbonyl formation). In both cases, the observedPRM fragmentation (Table 1, Figs. S19 and S21) revealed that both
indanyl and pyrrolidine moieties presented biotransformations. So,
it was assumed that M10 and M11 should have a hydroxyl in the
indanyl group and a ketone in the pyrrolidine, and vice-versa.
The product ions at m/z 86 (C4H8NOþ, common to M6 and M9),
98 (C5H8NOþ), 126 (C7H12NOþ, also shared with M9) confirmed the
ketone group to be in the pyrrolidine ring; the one at m/z 157
(shared with M1) confirmed the structure of M10. In a similar way,
M11 was elucidated based on product ions at m/z 173 (C12H13Oþ)
and 159 (C11H11Oþ, shared with M4 and M7) and 128 (C7H14NOþ,
common to M5), which indicated that this metabolite presented a
Fig. 3. Mass spectrometric behaviour of M8. (A) Proposed fragmentation pathway. (B) PRM spectrum at 50 eV.
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indanyl, respectively. The structures of M10 and M11 were
confirmed after proposing the fragmentation pathway for both
compounds (Figs. S20 and S22, respectively).
3.3.10. Metabolite M12
M12 was detected at m/z 286.1434 (C17H22NO3þ, 1.4 ppm),
being the compound that presented the lowest response. In this
case, only two product ions were observed (Fig. S23) at m/z 159
(shared with M7 and M11) and m/z 126 (shared with M10). M12
was then proposed as a compound with two ketone groups, one in
the indanyl moiety and the other in the pyrrolidine ring. The pro-
posed fragmentation pathway (Fig. S24) fitted with the structure
and fragmentation observed.
3.4. 5-PPDi metabolic fate
Once elucidated the 12 5-PPDi metabolites formed after pHH
incubation, the metabolic pathway of this compound was proposed
(Fig. 4). This indanyl-cathinone is hepatically metabolised mainly
through hydroxylation and oxidation processes.In the case of the pyrrolidine moiety, hydroxylation (M6),
oxidation (ketone formation, M10 and M12) and oxidative opening
(M9) occurred. These biotransformations have been reported for
pyrrolidine-cathinones, such as MDPV [19], a-PHP [21], a-PBP [17]
or 4-methoxy-a-PVP [25]. M3 and M4 corresponded to hydroxyl-
ations in the methyl or methylene groups of the alkylic chain,
biotransformations were also observed for MDPV [19], a-PVT [26],
PV8 [20] and a-PHP [21]. Nevertheless, no information about hy-
droxylations in the a-carbon of cathinones (M5) has been found in
literature. Regarding the indanyl moiety, hydroxylation (M1, M10),
ketone formation (M7, M11, M12) and oxidative ring-opening (M8)
were observed. These biotransformations are quite similar to those
observed for pyrrolidine moieties in literature. In some cases, more
than one biotransformation was found, such as hydroxylation plus
ketone formation (M10, M11) or formation of two ketones (M12).
At the end of the pHH incubation, the presence of 5-PPDi in
media was around 67% respect to its initial response, indicating a
relative high hepatic stability. In the case of the metabolites, M9
presented the higher response after 180 min (around 3.3% respect
to 5-PPDi initial response), together with M8 (3.2%), M4 (3.1%), M2
(1.6%) and M3 (1.4%). The remaining metabolites were found at
Fig. 4. Proposed metabolic pathway for 5-PPDi.
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tive response of 0.001%. These results show that the metabolic fate
of 5-PPDi goes to the generation of carboxylic acid that involves
ring-opening reactions (in this case, indanyl and pyrrolidine). Based
on these results, the potential biomarkers proposed for detecting
the consumption of 5-PPDi in intoxication cases by the analysis of
urine and blood samples are 5-PPDi itself and the metabolites M8
and M9. Both compounds are the major metabolites after pHH in-
cubation, andmay be expected to bemajor metabolites of 5-PPDi in
urine as well. Nevertheless, for analysis of urine samples, a previous
enzymatic hydrolysis with b-glucuronidase should be performed,
in order to de-conjugate M8/M9 glucuronide and detect the phase I
metabolites.
3.5. Metabolic behaviour of 3-FEA, 4-CEC and 4-CPrC
Data obtained in this work revealed that amphetamine 3-FEA
and the cathinone 3-CEC were not metabolised by the hepato-
cytes, probably due to the high polarity of both compounds.
Different in vitro experiments performed with similar compounds
also obtained few metabolites, and at low concentrations. As an
example, 3-FEA was compared with the amphetamines 5-APDB
[30] and 2-AEPB [31] using pHLM, which usually present higher
metabolic activity than pHH, identifying three metabolites per
compound. In the case of 4-CEC, analogous compounds, such as 4-
MEC [32], 3-BMC and 3-FMC [33], have been studied, showing they
are highly metabolised using pHLM (between 4-7 metabolites).
Nevertheless, these incubations were performed at high concen-
tration levels: 50 mM for 4-MEC [32] and 250 mM for 3-BMC and 3-
FMC [33]. In our work, the concentration tested (10 mM) was
selected after considering the typical dose used by authentic con-
sumers. Moreover, pHH were used in order to simulate the humanhepatic metabolic fate for the studied compounds. The absence of
metabolites for 3-FEA and 4-CEC suggest they are excreted as un-
altered compounds in human urine, and so, the consumption
biomarker proposed is the parent compound.
For the last compound studied, 4-CPrC, only two minor me-
tabolites were found, each corresponding to less than 0.5% of the
initial parent response at 180 min. The metabolite M1 corre-
sponded to the pyrrolidine moiety-hydroxylated metabolite, and
M2 to the pyrrolidine-ring opening followed by the formation of
carboxylic acid. Both biotransformations have been described in
literature for pyrrolidinophenone-derived cathinones, such as a-
pyrrolidinohexiophenone (a-PHP) [21], or 3,4-
methylenedioxypyrovalerone (MDPV) [19]. Supplementary files
contain the complete information about the 4-CPrC metabolism
study, including the proposed metabolic pathway (Fig. S25), PRM
fragmentation for parent compound and metabolites (Table S2,
Figs. S26e28), and the proposed fragmentation pathways
(Figs. S29e31).
4. Conclusion
This work reports the metabolic behaviour of four new psy-
choactive substances -3 synthetic cathinones and 1 amphetamine-
after incubationwith pooled human hepatocytes. The stimulants 3-
FEA and 4-CEC were not metabolised, and therefore the parent
compounds are proposed as biomarkers for monitoring the con-
sumption of these compounds. 4-CPrC also presented high hepatic
stability, and only 2 phase I metabolites were detected. The parent
compound and the oxidative ring-opening metabolite M2 seem to
be the most suitable consumption biomarkers. In relation to the
recently reported cathinone 5-PPDi, up to 12 phase I metabolites
were identified, all of them resulting from hydroxylation and
D. Fabregat-Safont et al. / Journal of Pharmaceutical Analysis 10 (2020) 147e156 155oxidation processes. The oxidative ring-opening metabolites M8
(indanyl ring-opening) andM9 (pyrrolidine ring-opening) were the
major metabolites detected in terms of response. Nevertheless, at
the end of the incubation, 5-PPDi gave around 67% of the initial
response, suggesting again a high resistance of synthetic cath-
inones to hepatic metabolism. For monitoring the use of 5-PPDi, the
parent compound and the metabolites M8 and M9 are proposed as
consumption biomarkers. It is worth to noticing that 5-PPDi pre-
sents an indanyl moiety, and to our knowledge this is the first
metabolic profile reported for an indanyl-based cathinone. The
information provided in this work will be useful in forensic and
clinical chemistry to focus the analytical determination of cath-
inones in biofluids, and also in other areas related to metabolic
pathways of new psychoactive substances, such as toxicology and
pharmacology.
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